On January 27, 2022 Optieum Biotechnologies reported that the company has been awarded "NEDO STS" grant from New Energy and Industrial Technology Development Organization (NEDO) (Press release, Optieum Biotechnologies, JAN 27, 2022, View Source [SID1234639138]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This grant was submitted with the support of ANRI, a venture capital. With this funding, we will continue to expand our platform technology and accelerate the development of in-house CAR-T cell programs.

We are committed to go beyond the limits of immuno-oncology drug development and deliver the most appropriate treatment for the cancer patients in needs.